TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8352177

Group type: EXPERIMENTAL
Intervention: Smoking status (smokers)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonsmoking status (nonsmokers)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infarct location
Number of subjects: 0
Study: 3306290

Group type: EXPERIMENTAL
Intervention: Org OD 14 (2.5 mg/day)
Number of subjects: 0
Study: 29248604

Group type: EXPERIMENTAL
Intervention: Stress ball intervention (group 2)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Music therapy intervention (group 3)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (group 1)
Number of subjects: 120
Study: 27491025

Group type: EXPERIMENTAL
Intervention: Everolimus plus reduced-dose cyclosporine (EVR group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Mycophenolate mofetil plus standard-dose cyclosporine (STD group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups (EVR and STD)
Number of subjects: 24
Study: 24631948

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (platinum-based, primarily single-agent carboplatin)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No adjuvant chemotherapy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Carboplatin/paclitaxel
Number of subjects: 120
Study: 22159017

Group type: EXPERIMENTAL
Intervention: DNA-based test
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: WHO simplified grading system (TF)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: RNA-based test
Number of subjects: 12
Study: 20729740

Group type: EXPERIMENTAL
Intervention: Pegylated-interferon and ribavirin treatment
Number of subjects: 145
Study: 18716855

Group type: EXPERIMENTAL
Intervention: Psychological risk and resilience factors combined with knee X-rays
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Resilience
Number of subjects: 275
Study: 16648917

Group type: EXPERIMENTAL
Intervention: Alcohol-based hand rubs
Number of subjects: 54

Group type: COMPARATOR
Intervention: Negative control (water)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sodium dodecyl sulfate (SDS) control
Number of subjects: 54
Study: 12674130

Group type: EXPERIMENTAL
Intervention: Estrogen-progestin hormone replacement therapy
Number of subjects: 16000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16000
Study: 11014413

Group type: EXPERIMENTAL
Intervention: Ibuprofen and caffeine
Number of subjects: 301

Group type: COMPARATOR
Intervention: Ibuprofen alone
Number of subjects: 301

Group type: COMPARATOR
Intervention: Caffeine alone
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study: 8989060

Group type: EXPERIMENTAL
Intervention: Salm-1 (50 micrograms of salmeterol, single dose)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Salm-2 (regular treatment with salmeterol for 1 week)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Plac-1 (single dose of placebo)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Plac-2 (regular treatment with placebo for 1 week)
Number of subjects: 8
Study: 1455910

Group type: EXPERIMENTAL
Intervention: 10 micrograms of vaccine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 100 micrograms of vaccine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 500 micrograms of vaccine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1000 micrograms of vaccine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All doses of vaccine
Number of subjects: 20
Study: 6365236

Group type: EXPERIMENTAL
Intervention: Clotrimazole 500 mg tablet
Number of subjects: 100

Group type: COMPARATOR
Intervention: Isoconazole 300 mg tablets (2 tablets)
Number of subjects: 100
Study: 29847356

Group type: EXPERIMENTAL
Intervention: Virtual Electrosurgery Skill Trainer (VEST)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study: 28830742

Group type: EXPERIMENTAL
Intervention: Valacyclovir (1.5G twice daily for 16 weeks)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 26348920

Group type: EXPERIMENTAL
Intervention: Unilateral Training Group (UG)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Bilateral Training Group (BG)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 43
Study: 25039544

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) plus saline
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate plus saline
Number of subjects: 107

Group type: COMPARATOR
Intervention: Intravenous saline
Number of subjects: 107
Study: 22709278

Group type: EXPERIMENTAL
Intervention: Voluntary virtual patient module
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control group (no access to virtual patient module)
Number of subjects: 226
Study: 20811340

Group type: EXPERIMENTAL
Intervention: Donepezil (cholinesterase inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17920357

Group type: EXPERIMENTAL
Intervention: High clopidogrel loading dose (>300 mg)
Number of subjects: 1567

Group type: COMPARATOR
Intervention: Standard clopidogrel loading dose (300 mg)
Number of subjects: 1567
Study: 12761725

Group type: EXPERIMENTAL
Intervention: Biofeedback therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical therapies (artificial sphincter procedures and dynamic graciloplasty)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newer, less invasive therapeutic approaches
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Understanding of risk factors
Number of subjects: 0
Study: 10761756

Group type: EXPERIMENTAL
Intervention: Cisplatin 80 mg/m2 day 1, etoposide 120 mg/m2 day 1‐3 (bolus therapy)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Continuous infusion of carboplatin 100 mg/m2/week for six weeks (infusional therapy)
Number of subjects: 120
Study: 8968699

Group type: EXPERIMENTAL
Intervention: Isoenergetic 1000 kJ (240 kcal) portions of test foods
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Test foods producing a higher insulin response
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Total carbohydrate content of foods
Number of subjects: 38
Study: 1598096

Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (t-PA) (100 mg)
Number of subjects: 20768

Group type: COMPARATOR
Intervention: Streptokinase (1.5 million units)
Number of subjects: 20768

Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin
Number of subjects: 20768

Group type: COMPARATOR
Intervention: No heparin
Number of subjects: 20768
Study: 6539187

Group type: EXPERIMENTAL
Intervention: 10 mg nifedipine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30854442

Group type: EXPERIMENTAL
Intervention: Belinostat (PXD‐101)
Number of subjects: 0
Study: 28554878

Group type: EXPERIMENTAL
Intervention: AR glasses
Number of subjects: 20

Group type: COMPARATOR
Intervention: PALS pocket reference cards
Number of subjects: 20
Study: 25843412

Group type: EXPERIMENTAL
Intervention: Treprostinil 250µM via cathodal iontophoresis (40mC/cm²)
Number of subjects: 24

Group type: COMPARATOR
Intervention: NaCl 0.9%
Number of subjects: 24
Study: 24640437

Group type: EXPERIMENTAL
Intervention: 1.5% arginine and 1450 ppm F as sodium monofluorophosphate in a dicalcium phosphate dihydrate base
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: 8.0% arginine and 1450 ppm F as sodium monofluorophosphate in a calcium carbonate base
Number of subjects: 119

Group type: COMPARATOR
Intervention: Commercially available fluoride dentifrice without arginine (1450 ppm F as sodium monofluorophosphate in a dical base)
Number of subjects: 119
Study: 21238825

Group type: EXPERIMENTAL
Intervention: Oral midazolam
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Non-randomized arm (midazolam)
Number of subjects: 44

Group type: COMPARATOR
Intervention: All groups (midazolam and placebo)
Number of subjects: 44
Study: 19473596

Group type: COMPARATOR
Intervention: Deferiprone tablet (GPO‐L‐ONE, 500 mg, 3 tablets)
Number of subjects: 24
Study: 17460145

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 1 g twice daily
Number of subjects: 248

Group type: COMPARATOR
Intervention: Azathioprine (75 to 100 mg/d)
Number of subjects: 248
Study: 17273657

Group type: EXPERIMENTAL
Intervention: Oral polymyxin (2.5 mg/kg in 4 daily doses for 7 days)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Oral polymyxin
Number of subjects: 25
Study: 11763939

Group type: EXPERIMENTAL
Intervention: Oral‐B CrossAction toothbrush
Number of subjects: 75

Group type: COMPARATOR
Intervention: Comparison toothbrushes (seven other toothbrushes)
Number of subjects: 75
Study: 8795324

Group type: COMPARATOR
Intervention: Ondansetron alone (4 mg bolus and 0.13 mg.ml‐1 in the morphine solution)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Droperidol alone (1.25 mg bolus and 0.05 mg.ml‐1 in the morphine solution)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination therapy (ondansetron and droperidol)
Number of subjects: 60
Study: 1352331

Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate topically and acetazolamide 125 mg orally
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 39
Study: 6507184

Group type: EXPERIMENTAL
Intervention: Naloxone (0.4 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study: 31569780

Group type: EXPERIMENTAL
Intervention: Comprehensive non-surgical periodontal therapy (test group; n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Professional tooth cleaning (control group; n = 20)
Number of subjects: 40
Study: 30059542

Group type: EXPERIMENTAL
Intervention: Spacing of cue-approach training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Massing schedule of cue-approach training
Number of subjects: 0
Study: 27053715

Group type: EXPERIMENTAL
Intervention: Zonisamide (300 mg/d)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 24767550

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF) pulpotomy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Mineral trioxide aggregate (MTA) pulpotomy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Both PRF and MTA
Number of subjects: 62
Study: 23428763

Group type: EXPERIMENTAL
Intervention: 50 mg of levobupivacaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 50 mg of levobupivacaine plus 8 mg of lornoxicam
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 50 mg of levobupivacaine plus 8 mg of lornoxicam and 8 mg of morphine
Number of subjects: 60
Study: 20698715

Group type: EXPERIMENTAL
Intervention: Erigeron breviscapus (EBHM) extract, 2 tablets three times a day for 6 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo, 2 tablets three times a day for 6 months
Number of subjects: 40
Study: 18757091

Group type: EXPERIMENTAL
Intervention: Heart rate ≥70 bpm
Number of subjects: 5438

Group type: EXPERIMENTAL
Intervention: Heart rate increase of 5 bpm
Number of subjects: 5438

Group type: COMPARATOR
Intervention: Heart rate <70 bpm
Number of subjects: 5438
Study: 15634721

Group type: EXPERIMENTAL
Intervention: 1-wk GH replacement therapy (9.5 microg/kg.d)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Baseline values or changes in erythrocyte SLC activity, adiponectin, leptin, and IGFBP-1
Number of subjects: 10
Study: 12890208

Group type: EXPERIMENTAL
Intervention: TL01 phototherapy and topical calcipotriol cream (50 microg g(‐1))
Number of subjects: 50

Group type: COMPARATOR
Intervention: TL01 phototherapy and topical emollient as placebo
Number of subjects: 50
Study: 10383531

Group type: EXPERIMENTAL
Intervention: Pancreatin minimicrospheres
Number of subjects: 37

Group type: COMPARATOR
Intervention: Pancreatin microspheres
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Pancreatin minimicrospheres and microspheres
Number of subjects: 37
Study: 8922305

Group type: EXPERIMENTAL
Intervention: Fecal diacylglycerol (DAG) concentrations
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dietary intake
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Percentage of calories from dietary fat
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fiber and calcium intake
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fecal DAG
Number of subjects: 12
Study: 1670740

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 30470568

Group type: EXPERIMENTAL
Intervention: Duloxetine 60mg/day + usual analgesic regimens
Number of subjects: 46

Group type: COMPARATOR
Intervention: Usual analgesic regimens (morphine±acetaminophen±gabapentin)
Number of subjects: 46
Study: 28917062

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5%
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% with adrenaline
Number of subjects: 89

Group type: COMPARATOR
Intervention: No infiltration (Control)
Number of subjects: 89
Study: 26366481

Group type: EXPERIMENTAL
Intervention: Levothyroxine (LT4) treatment
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 136
Study: 23410544

Group type: EXPERIMENTAL
Intervention: Successful strict rate control (resting heart rate <80 beats/min, during moderate exercise <110 beats/min)
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Failed strict rate control
Number of subjects: 614

Group type: COMPARATOR
Intervention: Lenient rate control (resting heart rate <110 beats/min)
Number of subjects: 614
Study: 22123031

Group type: EXPERIMENTAL
Intervention: mobiletype program (intervention group)
Number of subjects: 114

Group type: COMPARATOR
Intervention: attention comparison group (control group)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 114
Study: 20796302

Group type: EXPERIMENTAL
Intervention: IPTi‐SP
Number of subjects: 522

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 522
Study: 17439866

Group type: EXPERIMENTAL
Intervention: Nicotine replacement and brief behavioral intervention
Number of subjects: 383
Study: 15088993

Group type: EXPERIMENTAL
Intervention: Chronic fatigue syndrome patients (disabled from working)
Number of subjects: 1000
Study: 12138652

Group type: EXPERIMENTAL
Intervention: F-18 fluorodeoxyglucose positron emission tomography (FDG-PET)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional morphological imaging methods (ultrasonography, radiography, CT, MRI)
Number of subjects: 0
Study: 9926055

Group type: EXPERIMENTAL
Intervention: Intensive sector clients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive sector
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both sectors
Number of subjects: 0
Study: 7651645

Group type: EXPERIMENTAL
Intervention: Intraoperative autologous blood collection with autotransfusion (Cell Saver)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Historic controls (not using Cell Saver)
Number of subjects: 71
Study: 2699653

Group type: EXPERIMENTAL
Intervention: 1 mg/kg metoclopramide
Number of subjects: 50

Group type: COMPARATOR
Intervention: 2 mg/kg metoclopramide
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: High dosage of cisplatin (70-100 mg/m2) or ethylenediamine platinum II malonate (800-900 mg/m2)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both doses of metoclopramide
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Serum metoclopramide levels
Number of subjects: 50
Study: 989393

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mianserine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavior-oriented evaluation scale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-verbal behavior assessment
Number of subjects: 0
Study: 31216748

Group type: EXPERIMENTAL
Intervention: Action removal method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exhaustive approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shrink-Reduce approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: State-of-the-art approach
Number of subjects: 0
Study: 27902522

Group type: EXPERIMENTAL
Intervention: Topical use of Petroselinum crispum (parsley)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydroquinone cream
Number of subjects: 0
Study: 26425941

Group type: EXPERIMENTAL
Intervention: Leaflet
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Leaflet plus text message
Number of subjects: 254

Group type: COMPARATOR
Intervention: Usual waitlist control
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 254
Study: 23469148

Group type: EXPERIMENTAL
Intervention: 24 IU oxytocin
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 21377002

Group type: EXPERIMENTAL
Intervention: NTtrap stone occlusion device
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group (standard procedure)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 113
Study: 18990368

Group type: EXPERIMENTAL
Intervention: Microdose flare-up protocol (n = 45)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Antagonist multiple-dose protocol (n = 45)
Number of subjects: 90
Study: 17175305

Group type: EXPERIMENTAL
Intervention: Calcineurin inhibitor-free (CNI) protocol
Number of subjects: 3

Group type: COMPARATOR
Intervention: Standard triple therapy (tacrolimus, prednisone, mycophenolate mofetil)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Prednisone-free protocol
Number of subjects: 3
Study: 12634513

Group type: EXPERIMENTAL
Intervention: Clozapine and Olanzapine
Number of subjects: 29
Study: 16464205

Group type: EXPERIMENTAL
Intervention: Pharmaceutical interventions; compliance with economic evaluation guidance
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Modeling approach for pharmaceuticals; compliance with economic evaluation guidance
Number of subjects: 301

Group type: COMPARATOR
Intervention: Randomized controlled trials (RCTs) or modeling data; economic evaluations
Number of subjects: 301
Study: 9360688

Group type: EXPERIMENTAL
Intervention: Silver ring mounted on peritoneal dialysis catheter
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control group (no silver ring)
Number of subjects: 174
Study: 8256318

Group type: EXPERIMENTAL
Intervention: Transfusion with whole blood (n = 56)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Transfusion with blood free from leucocytes (n = 48)
Number of subjects: 197

Group type: COMPARATOR
Intervention: No blood transfusion (n = 93)
Number of subjects: 197
Study: 2439815

Group type: EXPERIMENTAL
Intervention: Bopindolol 2 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bopindolol 4 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pindolol 30 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bopindolol 8 mg
Number of subjects: 12
Study: 29862619

Group type: EXPERIMENTAL
Intervention: ipragliflozin 50 mg/day
Number of subjects: 143

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 143
Study: 27269306

Group type: EXPERIMENTAL
Intervention: Midazolam 0.05 mg/kg with 50% oxygen inhalation (group H)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Midazolam 0.05 mg/kg with normal air inhalation (group N)
Number of subjects: 21
Study: 25224360

Group type: EXPERIMENTAL
Intervention: eBST ≥ 11.4 ng/ml
Number of subjects: 900

Group type: COMPARATOR
Intervention: Normal BST
Number of subjects: 900
Study: 22571978

Group type: EXPERIMENTAL
Intervention: Fasting plasma insulin levels in men with nonamnestic or amnestic MCI
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Fasting plasma insulin levels in women with amnestic MCI
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: APOE ε4 genotype influence on insulin levels
Number of subjects: 549
Study: 19727797

Group type: EXPERIMENTAL
Intervention: L(-)-menthol (0.01%)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Orange-flavoured placebo solution
Number of subjects: 9
Study: 18922850

Group type: EXPERIMENTAL
Intervention: Hyperbaric articaine 84 mg
Number of subjects: 97

Group type: COMPARATOR
Intervention: Plain articaine 84 mg
Number of subjects: 97
Study: 16268751

Group type: EXPERIMENTAL
Intervention: Individualized intervention (printed advisory sent to clinicians at each patient visit)
Number of subjects: 4500

Group type: COMPARATOR
Intervention: General guideline implementation (education about guideline‐based drug recommendations)
Number of subjects: 4500
Study: 12160198

Group type: EXPERIMENTAL
Intervention: lisinopril
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: bendrofluazide
Number of subjects: 37
Study: 12539298

Group type: EXPERIMENTAL
Intervention: TSPP/STPP/HCS dentifrice (1% tetrasodium polyphosphate, 7% sodium tripolyphosphate, 0.243% sodium fluoride, 10% high cleaning silica)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo dentifrice (sodium fluoride/silica without stain removal ingredients)
Number of subjects: 91
Study: 10155230

Group type: EXPERIMENTAL
Intervention: Prophylactic intraaortic balloon pump (IABP) support
Number of subjects: 40

Group type: COMPARATOR
Intervention: Percutaneous cardiopulmonary bypass (PCPB) support
Number of subjects: 40
Study: 2354690

Group type: EXPERIMENTAL
Intervention: Low-dose iron supplements (18-20 mg iron/d) containing haem iron and non-haem iron
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Low-dose iron supplements (18-20 mg iron/d) containing non-haem iron only
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All low-dose iron supplements
Number of subjects: 45

Group type: COMPARATOR
Intervention: None of the supplements
Number of subjects: 45
Study: 6781157

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment with beta-receptor blocker propranolol, alone or in combination with dihydralazine and/or hydrochlorothiazide for 8 years.
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group treated with unsatisfactory results.
Number of subjects: 135
Study: 31754961

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Tongue-Retaining Device (TRD)
Number of subjects: 36
Study: 31464577

Group type: EXPERIMENTAL
Intervention: Intradiscal platelet-rich plasma (PRP) injections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0